Last $1.61 USD
Change Today +0.02 / 1.26%
Volume 341.0K
DSCO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 4:00 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DSCO) Snapshot

Open
$1.63
Previous Close
$1.59
Day High
$1.64
Day Low
$1.59
52 Week High
10/4/13 - $3.05
52 Week Low
05/9/14 - $1.51
Market Cap
136.5M
Average Volume 10 Days
346.1K
EPS TTM
$-0.74
Shares Outstanding
85.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DISCOVERY LABORATORIES INC (DSCO)

Related News

No related news articles were found.

discovery laboratories inc (DSCO) Related Businessweek News

No Related Businessweek News Found

discovery laboratories inc (DSCO) Details

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing life-saving products for critical-care patients with respiratory disease and care in pulmonary medicine. Its drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant), as well as in liquid, lyophilized, and aerosolized dosage forms; and develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company’s product includes SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants. It is also developing AEROSURF, a drug-device combination product that is in Phase IIa clinical trials for the treatment of RDS in premature infants; and AFECTAIR devices, which are novel disposable aerosol-conducting airway connectors for infants. The company has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

126 Employees
Last Reported Date: 03/17/14
Founded in 1992

discovery laboratories inc (DSCO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $493.3K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Senior Vice President of Research and Develop...
Total Annual Compensation: $336.3K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $303.5K
Compensation as of Fiscal Year 2013.

discovery laboratories inc (DSCO) Key Developments

Discovery Laboratories Inc. Approves an Amendment to Certificate of Incorporation

Discovery Laboratories Inc. announced that at the annual general meeting held on June 10, 2014, shareholders of the company approved an amendment to the company's certificate of incorporation to increase the number of authorized shares of common stock from 150 million shares to 250 million shares.

Discovery Laboratories, Inc. Announces Executive Appointments

Discovery Laboratories Inc. announced that it has strengthened its scientific leadership. Effective immediately, Steve Simonson, M.D., M.H.S. has joined the company as Vice President, Clinical Development, and Lawrence Weinstein has joined as Vice President, Medical Device Development. Dr. Simonson will oversee all aspects of clinical research, with responsibility for design and execution of clinical trials, and Mr. Weinstein will oversee all aspects of medical device research, design, and development. Their initial focus will be on the development of AEROSURF(R), Discovery Labs' combination drug/device product, which is currently in phase 2 development to provide KL4 surfactant therapy through nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS) in premature infants. Both Dr. Simonson and Mr. Weinstein will report to Dr. Russell Clayton, Discovery Labs' Senior Vice President, Research and Development. Most recently, Dr. Simonson was an Executive Director in the Molecule Development Group at Covance. Most recently, Mr. Weinstein served as President and Chief Operating Officer for ALR Technologies.

Discovery Laboratories, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Cash Flow Guidance for the Second Quarter of 2014

Discovery Laboratories Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of $31,000 against $72,000 for the same period a year ago. Operating loss was $10,763,000 against $12,620,000 for the same period a year ago. Net loss was $11,476,000 or $0.14 loss per common share against $12,635,000 or $0.29 loss per common share for the same period a year ago. The company provided cash flow guidance for the second quarter of 2014. The company anticipates operating cash outflows before financing activities of approximately $11 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCO:US $1.61 USD +0.02

DSCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.86 USD +0.11
View Industry Companies
 

Industry Analysis

DSCO

Industry Average

Valuation DSCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 388.2x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 116.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit www.discoverylabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.